Technical Analysis for NKTX - Nkarta, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | -4.25% | |
| Bollinger Band Squeeze | Range Contraction | -4.25% | |
| 20 DMA Resistance | Bearish | -5.09% | |
| Bollinger Band Squeeze | Range Contraction | -5.09% | |
| Gapped Up | Strength | -5.09% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.31% | |
| Bollinger Band Squeeze | Range Contraction | -0.31% | |
| Inside Day | Range Contraction | -0.31% |
| Alert | Time |
|---|---|
| Possible Inside Day | 3 days ago |
| Down 3% | 3 days ago |
| 60 Minute Opening Range Breakdown | 3 days ago |
| Fell Below 10 DMA | 3 days ago |
| 10 DMA Support | 3 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Lymphoma Virotherapy Gene Therapy Chimeric Antigen Receptor T Cell Natural Killer Cell Therapies For Cancer Chimeric Antigen Receptor Antigen CD19 Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Lymphoma Virotherapy Gene Therapy Chimeric Antigen Receptor T Cell Natural Killer Cell Therapies For Cancer Chimeric Antigen Receptor Antigen CD19 Tumor Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.24 |
| 52 Week Low | 1.28 |
| Average Volume | 1,102,667 |
| 200-Day Moving Average | 5.70 |
| 50-Day Moving Average | 8.97 |
| 20-Day Moving Average | 6.90 |
| 10-Day Moving Average | 6.62 |
| Average True Range | 0.67 |
| RSI (14) | 38.27 |
| ADX | 25.57 |
| +DI | 19.83 |
| -DI | 25.77 |
| Chandelier Exit (Long, 3 ATRs) | 6.31 |
| Chandelier Exit (Short, 3 ATRs) | 7.92 |
| Upper Bollinger Bands | 7.71 |
| Lower Bollinger Band | 6.10 |
| Percent B (%b) | 0.27 |
| BandWidth | 23.36 |
| MACD Line | -0.59 |
| MACD Signal Line | -0.70 |
| MACD Histogram | 0.1094 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.13 | ||||
| Resistance 3 (R3) | 7.18 | 7.03 | 7.03 | ||
| Resistance 2 (R2) | 7.03 | 6.88 | 7.00 | 7.00 | |
| Resistance 1 (R1) | 6.78 | 6.78 | 6.70 | 6.73 | 6.96 |
| Pivot Point | 6.63 | 6.63 | 6.59 | 6.60 | 6.63 |
| Support 1 (S1) | 6.38 | 6.48 | 6.31 | 6.33 | 6.10 |
| Support 2 (S2) | 6.23 | 6.38 | 6.21 | 6.06 | |
| Support 3 (S3) | 5.98 | 6.23 | 6.03 | ||
| Support 4 (S4) | 5.93 |
